Arthritis Treatments (Disease-Modifying Antirheumatic Drugs) DMARDs, Other Immune Modulators

Share this content:
ARTHRITIS TREATMENTS: DMARDS AND OTHER IMMUNE MODULATORS
Generic Brand Strength Form Dose
DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDs)
auranofin Ridaura 3mg caps Adults: Initially 6mg daily in 1−2 divided doses. If response inadequate after 6mos, may increase to 3mg 3 times daily. If still ineffective after 3mos, discontinue.
Children: Not recommended.
azathioprine Azasan 75mg, 100mg scored tabs Adults: 1mg/kg/day in 1–2 divided doses. After 6–8wks, if needed, increase by 0.5mg/kg/day increments every 4wks; max 2.5mg/kg/day. Maintenance: use lowest effective dose; can decrease by 0.5mg/kg/day (approx. 25mg daily) every 4wks.
Children: Not established.
Imuran 50mg scored tabs
cyclosporine Gengraf 25mg, 100mg caps* Adults: ≥18yrs: Give consistently with regard to meals and time of day. 1.25mg/kg twice daily; may increase by 0.5−0.75mg/kg/day after 8wks and again after 12wks; max 4mg/kg/day (many patients on concomitant methotrexate can be treated with doses of 3mg/kg/day or less). Dilute soln in a glass of room temp orange or apple juice. Reduce dose by 25−50% if adverse events (eg, hypertension or serum creatinine increases ≥30% above baseline) occur. Renal impairment: not recommended. Severe hepatic impairment: consider reducing dose.
Children: <18yrs: not established.
100mg/mL soln
Neoral 25mg, 100mg caps* Adults: ≥18yrs: Give consistently with regard to meals and time of day. 1.25mg/kg twice daily; may increase by 0.5−0.75mg/kg/day after 8wks and again after 12wks; max 4mg/kg/day Concomitant MTX: may treat with 3mg/kg/day or less. Reduce dose by 25−50% if adverse events (eg, hypertension or SCr increases ≥30% above baseline) occur.
Children: <18yrs: not established.
100mg/mL soln*
hydroxy-
chloroquine
Plaquenil 200mg tabs Adults: RA: Initially 400−600mg daily with food or milk. Lupus: Initially 400mg 1−2 times daily. Maintenance for both: 200−400mg daily.
Children: Not recommended.
leflunomide Arava 10mg, 20mg, 100mg tabs Adults: Arava-associated hepatotoxicity and myelosuppression (low-risk): give 100mg loading dose once daily for 3 days; then 20mg daily thereafter; (high-risk): give 20mg once daily without loading dose. Max 20mg/day. If not well tolerated, may reduce to 10mg daily.
Children: Not established.
methotrexate Otrexup 10mg/0.4mL, 15mg/0.4mL, 20mg/0.4mL, 25mg/0.4mL soln for SC inj Adults: 10−25mg once weekly using an oral, IM, SC, or IV form; max 30mg/wk. See entry for full instructions.
Children: <2yrs: not established. ≥2yrs: Initially 10mg/m² once weekly.
Rasuvo 7.5mg/0.15mL, 10mg/0.20mL, 12.5mg/0.25mL, 15mg/0.30mL, 17.5mg/0.35mL, 20mg/0.40mL, 22.5mg/0.45mL, 25mg/0.50mL, 27.5mg/0.55mL, 30mg/0.60mL soln for SC inj Adults: 7.5mg once weekly using oral or SC form. Use of alternative MTX forms: see entry for full labeling.
Children: <2yrs: not established. 2–16yrs: Initially 10mg/m² once weekly; Use of alternative MTX forms: see entry for full labeling.
Rheuma-
trex
2.5mg scored tabs Adults: Initially 7.5mg once weekly as a single dose, or a course of three 2.5mg doses at 12‑hr intervals once weekly; max 20mg/wk.
Children: <2yrs: not recommended. ≥2yrs: Initially 10mg/m² once weekly; max 20mg/m²/wk.
sulfasalazine Azulfidine
 EN
500mg enteric coated tabs Adults: Take after meals. Initially 500mg in the PM for 1wk, then 500mg in the AM & PM for 1wk, then 500mg in the AM and 1g in the PM for 1wk, then 1g in the AM & PM in 2 evenly divided doses.
Children: <6yrs: not recommended. ≥6yrs: Initially ¼ to ⅓ of maintenance dose; increase weekly. Maintenance: 30−50mg/kg/day in 2 evenly divided doses; max 2g/day.
TUMOR NECROSIS FACTOR (TNF) BLOCKERS
adalimumab Humira 10mg/0.2mL, 20mg/0.4mL, 40mg/0.4mL, 40mg/0.8mL, 80mg/0.8mL soln for SC inj Adults: ≥18yrs: 40mg every other week. RA (without MTX): may increase frequency to once weekly.
Children: <2yrs or <10kg: not recommended. 2−17yrs: (10kg−<15kg): 10mg every other week (10mg prefilled syringe should be used); (15−<30kg): 20mg every other week (20mg prefilled syringe should be used); (≥30kg): 40mg every other week.
certolizumab pegol Cimzia 200mg/mL soln for SC inj Adults: RA, psoriatic arthritis: 400mg (two 200mg inj at separate sites) SC on Day 1, then at Weeks 2 and 4, followed by 200mg every other week. Maintenance: may consider 400mg every 4wks. Ankylosing spondylitis: 400mg on Day 1, then at Weeks 2 and 4, followed by 200mg every 2wks or 400mg every 4wks.
Children: Not established.
200mg/vial pwd for SC inj after reconsti-
tution
etanercept Enbrel 25mg/vial pwd for SC inj after reconsti-
tution
Adults: 50mg SC once weekly
Children: <2yrs: not established. JIA: ≥2yrs: (<63kg): 0.8mg/kg (max 50mg) weekly; (≥63kg): 50mg weekly.
25mg/0.5mL, 50mg/mL soln for SC inj
golimumab Simponi 50mg/0.5mL, 100mg/mL soln for SC inj Adults: 50mg SC once monthly. May continue to use corticosteroids, non-biologic DMARDs, and/or NSAIDs during treatment.
Children: <18yrs: not established.
Simponi Aria 50mg/4mL soln for IV infusion Adults: Infuse over 30min. 2mg/kg IV at Weeks 0 and 4, then every 8wks thereafter. May continue to use corticosteroids, non-biologic DMARDs, and/or NSAIDs during treatment. RA: give with MTX. Psoriatic arthritis, ankylosing spondylitis: may give with or without MTX or other non-biologic DMARDs.
Children: <18yrs: not established.
infliximab Remicade 100mg/vial pwd for IV infusion after reconsti-
tution and dilution
Adults: Give by IV infusion over at least 2hrs. RA: 3mg/kg at weeks 0, 2, 6, then every 8wks. May increase to 10mg/kg or give every 4wks. Ankylosing spondylitis: 5mg/kg at weeks 0, 2, 6 then every 6wks. Psoriatic arthritis: 5mg/kg at weeks 0, 2, 6, then every 8wks. All: max 5mg/kg in CHF.
Children: Not recommended.
 
Generic Brand Strength Form Dose
INTERLEUKIN-1 RECEPTOR ANTAGONIST
anakinra Kineret 100mg/0.67mL soln for SC inj Adults: ≥18yrs: 100mg SC once daily. Severe renal impairment or ESRD (CrCl <30mL/min): may consider every other day dosing.
Children: <18yrs: not recommended.
canakinumab Ilaris 150mg/mL soln for SC inj Adults: Not recommended.
Children: <2yrs: not established. SJIA: ≥2yrs: (≥7.5kg): 4mg/kg (max 300mg) SC every 4wks.
INTERLEUKIN-12/23 RECEPTOR ANTAGONIST
ustekinumab Stelara 45mg/0.5mL, 90mg/1mL soln for SC inj Adults: ≥18yrs: 45mg SC once then 4wks later, followed by 45mg every 12wks. Co‑existent moderate-to-severe plaque psoriasis weighing >100kg: 90mg once then 4wks later, followed by 90mg every 12wks.
Children: <18yrs: not established.
INTERLEUKIN-17A RECEPTOR ANTAGONIST
ixekizumab Taltz 80mg/mL soln for SC inj Adults: ≥18yrs:  Psoriatic arthritis: 160mg (given as two 80mg SC inj) at Week 0, then 80mg every 4wks. With coexistent plaque psoriasis: 160mg at Week 0, then 80mg at Weeks 2, 4, 6, 8, 10, and 12, then 80mg every 4wks.
Children: <18yrs: not evaluated.
secukinumab Cosentyx 150mg/mL soln for SC inj Adults: ≥18yrs: Psoriatic arthritis with coexistent plaque psoriasis: 300mg (given as two 150mg inj) SC at Weeks 0, 1, 2, 3, and 4 then 300mg every 4wks. Other psoriatic arthritis (with a loading dose): 150mg SC at Weeks 0, 1, 2, 3, and 4 and every 4wks thereafter; (without a loading dose): 150mg every 4wks; consider a 300mg dose if psoriatic arthritis continues. Ankylosing spondylitis (with a loading dose): 150mg SC at Weeks 0, 1, 2, 3, and 4 and every 4wks thereafter; (without a loading dose): 150mg every 4wks.
Children: <18yrs: not evaluated.
150mg/vial pwd for SC inj after reconstitution
INTERLEUKIN-6 RECEPTOR INHIBITOR
sarilumab Kevzara 150mg/1.14mL, 200mg/1.14mL soln for SC inj Adults: RA: 200mg SC inj once every 2wks.
Children: Not established.
tocilizumab Actemra 20mg/mL soln for IV infusion after dilution Adults: RA: IV: Infuse over 60mins. Initially 4mg/kg every 4wks, then 8mg/kg every 4wks based on clinical response. Doses >800mg/infusion: not recommended. SC: <100kg: 162mg SC inj every other week, then give once weekly based on clinical response. ≥100kg: 162mg SC inj once weekly. Transitioning from IV to SC admin: give 1st SC dose instead of next scheduled IV dose.
Children: RA: not established. SJIA, PJIA: <2yrs or SC administration: not studied. ≥2yrs:  Infuse over 60mins. SJIA (<30kg): 12mg/kg every 2wks; (≥30kg): 8mg/kg every 2wks. PJIA (<30kg): 10mg/kg every 4wks; (≥30kg): 8mg/kg every 4wks.
162mg/
 
0.9mL
prefilled syringe
JANUS KINASE INHIBITOR
tofacitinib Xeljanz 5mg tabs Adults: 5mg twice daily
Children: Not established.
Xeljanz XR 11mg ext-rel tabs Adults: 11mg once daily.
Children: Not established.
PHOSPHODIESTERASE 4 INHIBITOR
apremilast Otezla 10mg, 20mg, 30mg tabs Adults: Active psoriatic arthritis: Day 1: 10mg in AM. Day 2: 10mg in AM and 10mg in PM. Day 3: 10mg in AM and 20mg in PM. Day 4: 20mg in AM and 20mg in PM. Day 5: 20mg in AM and 30mg in PM. Following on Day 6 and thereafter: 30mg twice daily (AM & PM).
Children: <18yrs: not established.
SELECTIVE COSTIMULATION MODULATOR
abatacept Orencia 250mg/vial pwd for IV infusion after reconsti-
tution and dilution
Adults: IV regimen: Give as IV infusion over 30 min at weeks 0, 2, and 4, then every 4wks. <60kg: 500mg. 60−100kg: 750mg. >100kg: 1g. SC regimen (may initiate with or without an IV loading dose): Following a single IV loading dose (based on body wt listed above), give the first 125mg SC inj within a day, then subsequently 125mg SC inj once weekly.
Children: IV regimen: give as IV infusion over 30min at weeks 0, 2, and 4, then every 4wks. <6yrs: not studied. 6–17yrs: (<75kg): 10mg/kg; (≥75kg): use adult dose; max 1g. SC regimen (initiate without an IV loading dose): <2yrs: not studied. ≥2yrs: (10–<25kg): 50mg once weekly; (25–<50kg): 87.5mg once weekly; (≥50kg); 125mg once weekly. ClickJect autoinjector: not studied in patients <18yrs.
50mg/0.4mL, 87.5mg/0.7mL, 125mg/mL prefilled syringe for SC inj
125mg/mL ClickJect autoinjector for SC inj
CD20 ANTIBODY
rituximab Rituxan 10mg/mL soln for IV infusion Adults: Give glucocorticoids 30min prior to each infusion. Concomitant MTX therapy: give two 1000mg IV infusions separated by 2wks. Subsequent courses should be given every 24wks or based on response, but not sooner than every 16wks.
Children: Not established.
NOTES

Key: JIA = Juvenile rheumatoid arthritis; MTX = methotrexate; RA = Rheumatoid arthritis; SJIA = Systemic juvenile idiopathic arthritis

*contains alcohol

†Not bioequivalent to all other forms of cyclosporine; do not interchange without physician supervision.

Not an inclusive list of medications, indications, and/or dosing details. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 2/2018)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs